跳至主要内容
临床试验/NL-OMON40980
NL-OMON40980已完成不适用

Does oral administration of dabigatran etexilate, a direct thrombin inhibitor, achieve clinical significant concentrations of dabigatran and thrombin inhibiting activity in vitreous and subretinal fluid? - Dabigatran & Ocular Accessibility

Oogziekenhuis Rotterdam0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Age >= 18 years,
  • - Informed consent,
  • - Needing surgery for a rhegmatogenous retinal detachment (scleral buckle surgery or vitrectomy)

排除标准

  • - Using other anticoagulants (e.g. acenocoumarol, heparin etc),
  • - Using medication that increases risk of GI bleeding (e.g. aspirin, NSAID*s, SSRI*s, oral corticosteroids).
  • - History of stomach ulcer/ bleeding
  • - Patients with renal function (CrCL) < 50 mL/min,
  • - Age > 75
  • - Hepatic impairment,
  • - Hypersensitivity to the active substance or to any of the excipients,
  • - Concomitant treatment with systemic ketoconazole, cyclosporine, itraconazole, tacrolimus and dronedarone,
  • - Lesion or condition at significant risk of major bleeding.

研究者

发起方
Oogziekenhuis Rotterdam

相似试验

进行中(未招募)
1 期
Does oral administration of dabigatran etexilate, a direct thrombin inhibitor, achieve significant levels and thrombin inhibiting activity in the eye?Ocular accessibility of dabigatran in patients with retinal detachment
EUCTR2014-000388-41-NLThe Rotterdam Eye Hospital28
已完成
不适用
Does oral administration of dabigatran etexilate, a direct thrombin inhibitor, achieve clinical significant concentrations of dabigatran and thrombin inhibiting activity in vitreous and subretinal fluid?Rhegmatogenous retinal detachment.
NL-OMON23085Het Oogziekenhuis RotterdamRotterdams Oogheelkundig Instituut24
已完成
不适用
Pharmacokinetics and *dynamics of Dabigatran Etexilate and Rivaroxaban in patients requiring PArenteral Nutrition (the PDER PAN study)anticoagulantblood thinner10014523
NL-OMON38688Academisch Medisch Centrum6
招募中
不适用
Pharmacokinetics and –dynamics of Dabigatran Etexilate and Rivaroxaban in patients requiring PArenteral Nutrition (the PDER PAN study)parenteral nutrition, thrombosis, pharmacokinetics, pharmacodynamics, anticoagulant
NL-OMON26342Academic Medical Center, Amsterdam, The Netherlands6
进行中(未招募)
1 期
ninterrupted dabigatran etexilate in comparison to uninterrupted warfarin in pulmonary vein ablation (RE-CIRCUIT)Patients with non-valvular atrial fibrillation (NVAF) undergoing catheter ablation for atrial fibrillationMedDRA version: 18.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 18.0Level: PTClassification code 10043634Term: Thrombosis prophylaxisSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2014-003890-40-ESBoehringer Ingelheim España, S.A.795